Chemotherapy News and Research

Latest Chemotherapy News and Research

NephRx receives new U.S. patent for NX002 to treat oral mucositis

NephRx Corporation today announced issuance of a new U.S. patent for its novel peptide NX002, which currently is in preclinical development for the treatment of oral mucositis.

23 Mar 2011

MnSOD oral drug can protect against lung cancer radiation therapy

Patients with advanced non-small cell lung cancer can safely take an experimental oral drug intended to protect healthy tissue from the effects of radiation, according to a study led by researchers at the University of Pittsburgh Cancer Institute and published in this month's issue of Human Gene Therapy.

23 Mar 2011

Spectrum's Prior Approval Supplement for Indium-111 ZEVALIN accepted for review by FDA

Spectrum Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Prior Approval Supplement containing data providing for the removal of the Indium-111 ZEVALIN® (ibritumomab tiuxetan) pre-treatment imaging evaluation, more commonly referred to as the "bioscan" requirement.

23 Mar 2011

Cellerant commences CLT-008 Phase I/II trial in patients with leukemia

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced the initiation of a Phase I/II clinical trial of CLT-008 in patients receiving intensive post-remission chemotherapy for high-risk leukemia or myelodysplasia.

23 Mar 2011

PRWP receives two new patents for Galectin-targeting compounds in the U.S., Australia

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that the Company has been granted two new patents, "Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer" in Australia and "Selectively Depolymerized Galactomannan Polysaccharide" in the United States.

23 Mar 2011

SGEN, Abbott enter collaboration agreement for ADC products

Seattle Genetics, Inc.today announced that it has entered into a collaboration agreement with Abbott under which Abbott will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate technology with antibodies to a single oncology target.

23 Mar 2011

CABC offers first-ever PEM-guided accessory for breast biopsy

The Center for Advanced Breast Care is the first comprehensive breast center in the Chicago area to add Positron Emission Mammography-guided biopsy capability to its already extensive breast cancer care services.

23 Mar 2011

Experts to showcase nursing education, practical innovations at Las Vegas national conference

Motivating and educating nurses to help them excel in their daily practice is the focus of this year's National Conference for Nurse Practitioners: The Conference for Primary and Acute Care Clinicians, May 11-14, 2011, at the Las Vegas Hilton in Las Vegas, NV.

22 Mar 2011

CTC counting can determine lung cancer aggressiveness, predict best treatment

CANCER RESEARCH UK scientists have found that counting the number of lung cancer cells circulating in the blood could determine how aggressive the cancer is and predict the best treatment to use.

22 Mar 2011

Patients with bone cancer can benefit from radical surgery

During a radical surgery to treat a rare bone cancer, surgeons at UC San Diego Health System and Moores Cancer Center removed 50 percent of a patient's pelvis. Instead of amputating the connected leg, the surgical team, comprised of orthopaedic, vascular and urologic experts, saved the entire limb. The patient was able to walk with assistance five weeks after surgery.

22 Mar 2011

Study: Stem cell transplant may benefit patients with rapidly progressive MS

A long term study reports about the effectiveness of replacing bone marrow, purposely destroyed by chemotherapy, with autologous stem cell rescue for people with aggressive forms of multiple sclerosis.

22 Mar 2011

BMY's ipilimumab Phase III study against metastatic melanoma meets primary endpoint

Bristol-Myers Squibb Company today announced that a clinical trial -- known as study 024 -- of its investigational compound ipilimumab has met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma.

22 Mar 2011

Cephalon to acquire Gemin X Pharmaceuticals

Cephalon, Inc. announced today that it has signed a definitive merger agreement under which it will acquire all of the outstanding capital stock of Gemin X Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing first-in-class cancer therapeutics, for $225 million cash on a cash-free, debt-free basis. Gemin X stockholders could also receive up to $300 million in cash payments upon the achievement of certain regulatory and sales milestones.

22 Mar 2011

Sarsia Seed provides follow-up funding for APIM Therapeutics

APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.

21 Mar 2011

Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from a Phase II clinical trial of intravenous Phenoxodiol in combination with cisplatin in women with platinum-resistant ovarian cancer.

21 Mar 2011

$CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma$

CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma

Cell Therapeutics, Inc. today announced that it has initiated its randomized pivotal trial of pixantrone for the treatment of relapsed/refractory diffuse large B-cell lymphoma ("DLBCL").

21 Mar 2011

Polaris initiates ADI-PEG 20 Phase 2 trial in patients with malignant mesothelioma

Polaris Group announced today the enrollment of the first patient in a Phase 2 clinical trial of ADI-PEG 20, the company's novel enzyme-based treatment for malignant mesothelioma.

19 Mar 2011

Cancer Care Partners first in U.S. to use new, advanced cancer treatment

On March 7, 2010, Cancer Care Partners became the first cancer center in the United States to use the new TomotherapyHD, a comprehensive, image guided radiation therapy system that enables Cancer Care Partners to more efficiently treat complex tumors with improved precision.

18 Mar 2011

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

Amgen has received notice that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for Amgen's application to extend the marketing authorization in Europe for Vectibix® (panitumumab) to include combination with chemotherapy for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC).

18 Mar 2011

GHDX presents Oncotype DX breast cancer test study results at St. Gallen conference

Genomic Health, Inc. today announced results from nine studies utilizing the Oncotype DX test in early-stage breast cancer patients at the 12th Annual St. Gallen International Breast Cancer Conference in St. Gallen, Switzerland.

18 Mar 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

NephRx receives new U.S. patent for NX002 to treat oral mucositis

MnSOD oral drug can protect against lung cancer radiation therapy

Spectrum's Prior Approval Supplement for Indium-111 ZEVALIN accepted for review by FDA

Cellerant commences CLT-008 Phase I/II trial in patients with leukemia

PRWP receives two new patents for Galectin-targeting compounds in the U.S., Australia

SGEN, Abbott enter collaboration agreement for ADC products

CABC offers first-ever PEM-guided accessory for breast biopsy

Experts to showcase nursing education, practical innovations at Las Vegas national conference

CTC counting can determine lung cancer aggressiveness, predict best treatment

Patients with bone cancer can benefit from radical surgery

Study: Stem cell transplant may benefit patients with rapidly progressive MS

BMY's ipilimumab Phase III study against metastatic melanoma meets primary endpoint

Cephalon to acquire Gemin X Pharmaceuticals

Sarsia Seed provides follow-up funding for APIM Therapeutics

Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer

CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma

Polaris initiates ADI-PEG 20 Phase 2 trial in patients with malignant mesothelioma

Cancer Care Partners first in U.S. to use new, advanced cancer treatment

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

GHDX presents Oncotype DX breast cancer test study results at St. Gallen conference

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in